The clinical trial: Deceitful, disputable, unbelievable, unhelpful, and shameful - What next?

Controlled Clinical Trials

Volumn 22, Issue 6, 2001, Pages 593-604

  Horton, Richard ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; GENE THERAPY; HEALTH PRACTITIONER; HUMAN; INFORMED CONSENT; MALPRACTICE; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL LITERATURE; PARKINSON DISEASE; PATIENT CARE; PRODUCTIVITY; REVIEW; SAFETY; TREATMENT FAILURE;

EID: 0035216934     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(01)00175-1     Document Type: Article

References (52)

1. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease
2. Retraction: Interferon alfa-2b ... in Behçet's disease
3. Breast cancer researcher admits falsifying data
4. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications
5. Retraction
6. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study
7. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study
8. Scientific misconduct: Exaggerated fear but still real and requiring a proportionate response
9. Fraud in medical research: An international survey of biostatisticians
10. Fraud is bad, studying fraud is hard
11. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
12. Cell therapy for Parkinson's disease
13. Trial and error
14. Pumped back to life
15. Coverage by the news media of the benefits and risks of medications
16. Improving the quality of reporting of randomized controlled trials: The CONSORT statement
17. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
18. Subgroup analysis and other (mis)uses of baseline data in clinical trials
19. The quality of reporting in published cost-utility analyses, 1976-1997
20. The standard of reporting of health-related quality of life in clinical cancer trials
21. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement
22. Uneasy alliance: Clinical investigators and the pharmaceutical industry
23. Is academic medicine for sale?
24. Discussion sections in reports of controlled trials published in general medical journals
25. Patients' responses to risk information about the benefits of treating hypertension
26. The interpretive turn
27. The grammar of interpretive medicine
28. The unstable medical research paper
29. The rhetoric of research
30. Common sense and figures: The rhetoric of validity in medicine
31. The shame of medical research
32. Gene therapy on trial
33. Protecting research subjects - What must be done
34. Breaking the camel's back: Multicenter clinical trials and local IRBs
35. It's official: Evaluative research must become part of routine care in the NHS
36. The tightening grip of big pharma
37. Conflicts of interest policies in science and medical journals: Editorial practices and author disclosures
38. Scientists often mum about ties to industry
39. Marketing medicines through randomized controlled trials: The case of interferon
40. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials
41. Clinicians' attitudes to recruitment to randomized trials in cancer care
42. Ethical aspects of clinical trials: The attitudes of participants in two non-cancer trials
43. Results of an international study to improve communication about randomized clinical trials of cancer therapy
44. The extent of written trial information: Preferences among potential and actual trial subjects
45. Hybrid study designs and RCT variants
46. What do the people think (and know) about informed consent for participation in a medical trial
47. Conducting randomized trials in general practice: Methodological and practical issues
48. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries